Hong Kong General Merchandise and Department Stores Stock News

SEHK:9992
SEHK:9992Specialty Retail

Is Pop Mart International Group (SEHK:9992) Price Justified After Its Strong Multi‑Year Share Surge?

Many investors are considering whether Pop Mart International Group shares still represent good value after a strong run, or whether the price has already moved ahead of the fundamentals. The stock last closed at HK$217.2, with returns of 0.8% over 7 days, an 11.1% decline over 30 days, 12.5% year to date and 71.9% over 1 year, along with a very large 3-year return. Recent attention has focused on how Pop Mart fits into consumer trends in collectibles and branded merchandise, with investors...
SEHK:3918
SEHK:3918Hospitality

NagaCorp (SEHK:3918) Net Margin Surge Tests Single Market Risk Narratives

NagaCorp (SEHK:3918) has put up a solid set of FY 2025 numbers, with first half revenue of US$320.6 million and basic EPS of US$0.0336, set against reported earnings growth of 182.8% year over year and a five year compound growth rate of 45.7% per year. The company has seen revenue move from US$252.9 million in the second half of 2024 to US$320.6 million in the first half of 2025, while basic EPS shifted from US$0.0250 to US$0.0336 over the same periods. Investors will be weighing these...
SEHK:386
SEHK:386Oil and Gas

Is It Time To Reassess Sinopec (SEHK:386) After The Recent Share Price Pullback?

Wondering whether China Petroleum & Chemical at HK$4.53 still offers value, or if the easy gains are behind it? This article walks through what the current price really reflects. The stock has seen a 5.0% decline over the last 7 days and a 16.3% decline over the last 30 days, yet it shows returns of 15.5% over 1 year, 23.5% over 3 years and 67.3% over 5 years. Recent market conversations around China Petroleum & Chemical have focused on how its share price performance lines up with broader...
SEHK:6990
SEHK:6990Biotechs

Is It Time To Reassess Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) After Recent Share Price Weakness?

Wondering whether Sichuan Kelun-Biotech Biopharmaceutical is still priced attractively, or if the easy value has already been taken? This breakdown focuses squarely on what you are paying versus what you are getting. The share price recently closed at HK$397.60, after a 4.4% decline over the last week and a 4.6% decline over the past month, while the 1 year return sits at 52.6%. Recent news coverage has focused on Sichuan Kelun-Biotech Biopharmaceutical in the context of investor interest in...
SEHK:6862
SEHK:6862Hospitality

Is Haidilao International Holding (SEHK:6862) Attractive After Mixed Price Moves And DCF Upside?

Wondering if Haidilao International Holding at HK$15.85 is a bargain or a value trap? This article breaks down what the current price might actually reflect. The stock has had a mixed run, with a 10% year-to-date gain alongside 1% and 6% declines over the past 7 days and 30 days, and a 2.6% decline over the last year plus a 64.6% decline over five years that many investors still have in mind. Recent coverage has focused on Haidilao International Holding as a Hong Kong listed consumer...
SEHK:2869
SEHK:2869Real Estate

Greentown Service Group SEHK 2869 Margin Gain Questions Cautious Growth Narratives

Greentown Service Group (SEHK:2869) has put fresh numbers on the board for FY 2025, with first half revenue of about C¥9.3b and basic EPS of C¥0.19 setting the tone for its latest earnings update. The company has seen first half revenue move from C¥8.2b in 2023 to C¥8.8b in 2024 and then to C¥9.3b in 2025. Over the same periods, basic EPS shifted from C¥0.13 to C¥0.16 and then to C¥0.19, giving a clear view of how the top and bottom line have tracked together. For investors, the current...
SEHK:866
SEHK:866Oil and Gas

A Look At China Qinfa Group (SEHK:866) Valuation After Its Recent Follow On Equity Offering

China Qinfa Group (SEHK:866) has completed a follow on equity offering and raised HK$315.9 million through a subsequent direct listing of 90,000,000 new ordinary shares at HK$3.51 each, expanding its share capital base. See our latest analysis for China Qinfa Group. At a share price of HK$3.94, China Qinfa Group has seen a 10.67% one-month share price return and a roughly 18x one-year total shareholder return, with momentum building over the past quarter as investors react to the capital...
SEHK:6963
SEHK:6963Insurance

A Look At Sunshine Insurance Group (SEHK:6963) Valuation After Annual Results And Final Dividend Proposal

Sunshine Insurance Group (SEHK:6963) just released its full year 2025 results alongside a proposed final cash dividend of RMB 0.19 per ordinary share, a pairing that gives investors fresh income and earnings context. See our latest analysis for Sunshine Insurance Group. The latest HK$3.71 share price comes after a 1-day share price return of 0.54%, with the dividend and earnings announcement likely shaping how investors view Sunshine Insurance Group's risk and income profile. Despite a 30-day...
SEHK:2377
SEHK:2377Commercial Services

China Boqi Environmental (SEHK:2377) Margin Improvement Challenges Long‑Term Earnings Drift Narrative

China Boqi Environmental (Holding) (SEHK:2377) has posted its FY 2025 first half numbers with revenue of C¥1,058.5 million and basic EPS of C¥0.166, against trailing twelve month revenue of C¥2,260.0 million and EPS of C¥0.285 that sit alongside a 20.6% uplift in earnings and an 11.7% net margin over the last year. The company has seen revenue move from C¥949.4 million in 1H FY 2024 to C¥1,058.5 million in 1H FY 2025, while basic EPS moved from C¥0.114 to C¥0.166 over the same halves. This...
SEHK:2567
SEHK:2567Software

Qiniu (SEHK:2567) Loss Narrows To C¥33.4m Challenging Persistent Bearish Narratives

Qiniu (SEHK:2567) has opened FY 2025 with first half revenue of C¥829.4 million and a basic EPS loss of C¥0.02 per share, alongside a net income loss of C¥33.4 million. This sets a cautious tone for investors watching the company’s path toward profitability. The company has seen first half revenue move from C¥710.4 million in FY 2024 to C¥829.4 million in FY 2025, while basic EPS shifted from a loss of C¥0.41 to a smaller loss of C¥0.02. This frames a set of results where revenue scale and...
SEHK:2282
SEHK:2282Hospitality

MGM China Holdings (SEHK:2282) Margin Stability Tests Bullish Growth Narratives

Earnings snapshot and recent momentum MGM China Holdings (SEHK:2282) has put fresh numbers on the board for FY 2025, with first half revenue of about HK$16.7b, basic EPS of HK$0.63 and net income of HK$2.4b setting the tone for the year. The business has seen revenue move from roughly HK$16.2b in 1H 2024 to HK$15.2b in 2H 2024 and then to HK$16.7b in 1H 2025, while basic EPS shifted from HK$0.71 to HK$0.50 and then HK$0.63 over the same periods. This gives a clear sense of how headline growth...
SEHK:6862
SEHK:6862Hospitality

Haidilao’s World’s Strongest Brand Title Versus Its Tougher Share Record

Haidilao International Holding has been named the World’s Strongest Restaurant Brand for 2024. The recognition highlights the company’s brand strength beyond its usual financial headlines. The stock, traded under ticker SEHK:6862, last closed at HK$15.85. For investors tracking SEHK:6862, this brand accolade arrives after a mixed share price record. The stock is up 10.0% year to date, while the 1 year return stands at a 2.6% decline and the 5 year return at a 64.6% decline, with the current...
SEHK:9660
SEHK:9660Software

Horizon Robotics (SEHK:9660) Heavy C¥5.2b Loss Tests Bullish Profitability Narratives

Horizon Robotics (SEHK:9660) has reported FY 2025 first half results with revenue of C¥1.6b and a basic EPS loss of C¥0.42, setting a clear focus on how growth is feeding through to the bottom line. The company has seen revenue move from C¥934.6m in 1H 2024 to C¥1.4b in 2H 2024 and C¥1.6b in 1H 2025, while EPS has swung from a loss of C¥1.81 in 1H 2024 to a profit of C¥1.17 in 2H 2024 before reverting to a loss, so investors are watching how quickly these top line gains can translate into...
SEHK:867
SEHK:867Pharmaceuticals

China Medical System Wins Desidustat Approval Raising Nephrology Growth Questions

China Medical System Holdings (SEHK:867) has received marketing approval in China for Desidustat Tablets, an oral treatment for renal anaemia in non dialysis chronic kidney disease patients. The approval adds a new drug to the company’s nephrology portfolio and targets a major unmet medical need in China. China Medical System Holdings is drawing fresh attention after this new approval, with the share price at HK$13.49 and a 1 year return of 81.4%. The stock has also seen a 6.1% gain over...
SEHK:338
SEHK:338Chemicals

Sinopec Shanghai Petrochemical (SEHK:338) Q4 TTM Loss Of C¥1.4b Reinforces Bearish Narratives

Sinopec Shanghai Petrochemical (SEHK:338) closed FY 2025 with fourth quarter revenue of C¥16.7b and a basic EPS loss of C¥0.094801 per share, alongside net income excluding extra items of a C¥1.0b loss. This puts profitability under pressure at the current share price of HK$1.37. Over recent periods, the company has seen quarterly revenue move from C¥21.1b in Q4 2024 to C¥16.7b in Q4 2025, while quarterly EPS shifted from a C¥0.03468 profit to a C¥0.094801 loss. This may lead investors to...
SEHK:1033
SEHK:1033Energy Services

Sinopec Oilfield Service (SEHK:1033) Q4 Loss And 0.8% Margin Test Bullish Growth Narratives

Sinopec Oilfield Service (SEHK:1033) has released its FY 2025 numbers with fourth quarter revenue of about C¥25.5b and a small loss, as Basic EPS slipped to C¥0.000573, compared with C¥25.6b of revenue and Basic EPS of C¥0.002278 in the same quarter a year earlier. Over recent periods the company has seen quarterly revenue move from roughly C¥18.1b in Q3 2024 to C¥18.1b in Q3 2025 and EPS shift from C¥0.012 to C¥0.009076, while trailing twelve month EPS sits at C¥0.035 on revenue of about...
SEHK:1606
SEHK:1606Diversified Financial

A Look At China Development Bank Financial Leasing’s Valuation After Recent Share Price Moves

Recent share performance and valuation context China Development Bank Financial Leasing (SEHK:1606) has drawn investor attention after a recent 1.4% daily gain, contrasting with a month return of about 4.5% decline and a past 3 months slide of roughly 11.4%. At a last close of HK$1.48 and an estimated intrinsic discount of about 75%, the leasing group, which generates CN¥16,166.205 in revenue and CN¥5,022.752 in net income, now screens as a higher value score name. See our latest analysis for...
SEHK:1548
SEHK:1548Life Sciences

Genscript’s 2025 Profit Swing And mRNA Expansion Might Change The Case For Investing In Genscript Biotech (SEHK:1548)

Genscript Biotech has reported its full-year 2025 results, with sales rising to US$959.53 million while the company moved from a prior-year net income of US$2.96 billion to a net loss of US$532.83 million, alongside higher basic and diluted losses per share. A key driver of this sharp swing in reported profitability is the absence of the previous year’s very large one-time unrealised gain from deconsolidation, which means the latest figures chiefly reflect the underlying operating profile...